Comparative Pharmacology
Head-to-head clinical analysis: CLEVIPREX versus DILACOR XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLEVIPREX versus DILACOR XR.
CLEVIPREX vs DILACOR XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cleviprex (clevidipine) is a dihydropyridine L-type calcium channel blocker with high vascular selectivity. It inhibits calcium influx into vascular smooth muscle cells, causing arterial vasodilation and reduced peripheral vascular resistance.
Diltiazem inhibits calcium ion influx across cardiac and vascular smooth muscle cells, resulting in dilation of coronary and systemic arteries, decreased myocardial contractility, and reduced sinoatrial and atrioventricular conduction velocity.
Initiate intravenous infusion at 1-2 mg/kg/hr, titrate by 0.5-1 mg/kg/hr every 90 minutes up to maximum 32 mg/kg/hr. Maintenance dose: 4-6 mg/kg/hr. Route: IV. Frequency: continuous infusion.
180 to 240 mg orally once daily, administered on an empty stomach; maximum dose 480 mg once daily.
None Documented
None Documented
Terminal elimination half-life: 2.7 minutes (dihydropyridine ring reduction) and 15 minutes (ester hydrolysis); clinical context: rapid offset allows precise titration
Terminal half-life: 6-12 hours (prolonged in elderly, hepatic impairment, or with CYP3A4 inhibitors)
Renal: 63–73% as metabolites, fecal: 7–10%, unchanged drug in urine: <1%
Renal (70% as metabolites, 3-4% as unchanged drug); biliary/fecal (25-30%)
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker